Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR

被引:1
|
作者
Muniz-Saenz-Diez, Javier [1 ]
Ezponda, Ana [2 ]
Caballeros, Meylin [3 ]
de la Fuente, Ana [4 ]
Gavira, Juan J. [1 ]
Bastarrika, Gorka [2 ]
机构
[1] Clin Univ Navarra, Dept Cardiol, Ave Pio XII 36, Pamplona 31007, Spain
[2] Clin Univ Navarra, Dept Radiol, Pamplona, Spain
[3] Clin Univ Navarra, Dept Radiol, Madrid, Spain
[4] Clin Univ Navarra, Dept Cardiol, Madrid, Spain
来源
关键词
Coronary artery disease; Myocardial perfusion; Regadenoson; Perfusion cardiac magnetic resonance; Drug safety; CORONARY-ARTERY-DISEASE; HEART-RATE RESPONSE; DIAGNOSTIC PERFORMANCE; A(2A) AGONIST; DOUBLE-BLIND; ADENOSINE; TRIAL; TOLERABILITY; TOLERANCE; MR;
D O I
10.1007/s10554-023-02877-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Owing to its pharmacodynamics and posology, the use of regadenoson for stress cardiac magnetic resonance (CMR) has potential advantages over other vasodilators. We sought to evaluate the safety, hemodynamic response and diagnostic performance of regadenoson stress-CMR in routine clinical practice. All regadenoson stress-CMR examinations performed between May 2017 and July 2020 at our institution were retrospectively reviewed. A total of 698 studies were included for the final analysis. A conventional stress/rest protocol was performed using a 1.5T MRI scanner (Magnetom Aera, Siemens Healthineers, Erlangen, Germany). Adverse events, clinical symptoms, and hemodynamic response were assessed. Diagnostic accuracy of the test was evaluated in patients who underwent invasive coronary angiography. Nearly half of patients (48.5%) remained asymptomatic. Most common clinical symptoms included dyspnea (137, 19.6%), chest pain (116, 16.6%) and flushing (44, 6.3%). Two patients (0.28%) could not complete the examination due to severe hypotension or unbearable chest pain. Overall, an increase in heart rate (HR) response (36.2% [IQR: 22.5?50.9]) and a decrease in systolic and diastolic blood pressure (BP) (median systolic BP response of -5% [IQR: -11.5-0.6]; median diastolic BP response of -6.3 mmHg [IQR: -13.4-0]) was observed. Patients with symptoms induced by regadenoson showed higher HR response (40.3%, IQR: 26.4?56.1 vs. 32.4%, IQR: 19-45.6, p < 0.001), whereas a blunted HR response was observed in diabetic (29.6%, IQR: 18.4?42 p < 0.001), obese (31.7%, IQR: 20.7?46.2 p = 0.005) and patients aged 70 years or older (32.9%, IQR: 22.6?43.1 p < 0.001). Overall, regadenoson stress-CMR showed 95.65% (IQ 91.49?99.81) sensitivity, 54.84% (IQ 35.71?73.97) specificity, 86.99% (IQ 82.74?94.68) positive predictive value, and 77.27% (IQ 57.49?97.06) negative predictive value for detecting significant coronary stenosis as compared with invasive coronary angiography. Regadenoson is a well-tolerated vasodilator that can be safely employed for stress perfusion CMR, with high diagnostic performance.
引用
收藏
页码:1765 / 1774
页数:10
相关论文
共 50 条
  • [31] Are rest perfusion images needed in stress perfusion CMR?
    Moharem-Elgamal, S.
    Pontecorboli, G.
    Biglino, G.
    Milano, E. G.
    De Garate, E.
    Harries, I.
    Dastidar, A.
    Baritussio, A.
    Bucciarelli-Ducci, C.
    EUROPEAN HEART JOURNAL, 2017, 38 : 91 - 91
  • [32] Determinants of myocardial perfusion reserve measured from coronary sinus phase-contrast imaging during regadenoson stress CMR
    Michael A Bauml
    Jaehoon Chung
    Vineet Dandekar
    Andrew W Ertel
    Carolyn Dickens
    Rosalia C Gonzalez
    Afshin Farzaneh-Far
    Journal of Cardiovascular Magnetic Resonance, 16 (Suppl 1)
  • [33] Safety and Efficacy of Regadenoson for Pediatric Stress Perfusion Cardiac MRI with Quantification of Myocardial Blood Flow
    Patel, Shivani G.
    Husain, Nazia
    Rigsby, Cynthia K.
    Robinson, Joshua D.
    CHILDREN-BASEL, 2022, 9 (09):
  • [34] Safety, tolerability and feasibility of adenosine stress CMR in high-risk patients
    Amardeep Ghosh Dastidar
    Alexander Carpenter
    Catherine R Wilson
    Nauman Ahmed
    Chris B Lawton
    Mark Hamilton
    Chiara Bucciarelli-Ducci
    Journal of Cardiovascular Magnetic Resonance, 17 (Suppl 1)
  • [35] Feasibility, safety and effectiveness in measuring microvascular resistance with regadenoson
    Lachmann, Vera
    Heimann, Marc
    Jung, Christian
    Zeus, Tobias
    Verde, Pablo Emilio
    Kelm, Malte
    Boenner, Florian
    CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2019, 71 (03) : 299 - 310
  • [36] Stress perfusion cardiac MRI with regadenoson and gadofoveset trisodium
    Bradley D Allen
    Neil Chatterjee
    Jad Bou Ayache
    Benjamin H Freed
    Daniel C Lee
    Timothy Carroll
    Michael Markl
    Jeremy D Collins
    James C Carr
    Journal of Cardiovascular Magnetic Resonance, 17 (Suppl 1)
  • [37] Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test
    Partington, Sara L.
    Lanka, Viswanatha
    Hainer, Jon
    Blankstein, Ron
    Skali, Hicham
    Forman, Daniel E.
    Di Carli, Marcelo F.
    Dorbala, Sharmila
    JOURNAL OF NUCLEAR CARDIOLOGY, 2012, 19 (05) : 970 - 978
  • [38] Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test
    Sara L. Partington
    Viswanatha Lanka
    Jon Hainer
    Ron Blankstein
    Hicham Skali
    Daniel E. Forman
    Marcelo F. Di Carli
    Sharmila Dorbala
    Journal of Nuclear Cardiology, 2012, 19 : 970 - 978
  • [39] Feasibility and clinical efficacy of Regadenoson stress myocardial perfusion imaging as an alternative to Dobutamine in patients with obstructive Airway disease
    Panchadar, S.
    Biswas, G.
    Mohammad, M. H.
    Al-Ajmi, J.
    Al-Sayed, Y. M.
    Shukkur, A. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S200 - S200
  • [40] Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis
    Palani, Gurunanthan
    Husain, Zehra
    Salinas, Rafael Cabrera
    Karthikeyan, Vanji
    Karthikeyan, Aarthee S.
    Ananthasubramaniam, Karthik
    JOURNAL OF NUCLEAR CARDIOLOGY, 2011, 18 (04) : 605 - 611